SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-21-003066
Filing Date
2021-11-04
Accepted
2021-11-04 16:13:00
Documents
61
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fate-20210930.htm   iXBRL 10-Q 2945121
2 EX-31.1 fate-ex31_1.htm EX-31.1 14418
3 EX-31.2 fate-ex31_2.htm EX-31.2 14529
4 EX-32.1 fate-ex32_1.htm EX-32.1 10217
  Complete submission text file 0000950170-21-003066.txt   12510064

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fate-20210930_def.xml EX-101.DEF 255124
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fate-20210930_cal.xml EX-101.CAL 46770
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fate-20210930.xsd EX-101.SCH 60444
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fate-20210930_lab.xml EX-101.LAB 488794
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fate-20210930_pre.xml EX-101.PRE 383532
10 EXTRACTED XBRL INSTANCE DOCUMENT fate-20210930_htm.xml XML 3227491
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 651311552 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 211380095
SIC: 2836 Biological Products, (No Diagnostic Substances)